FDA Approves First Oral Therapy For Prevention of HAE Attacks

When the FDA approved BioCryst Pharmaceuticals, Inc.’s Orladeyo (berotralstat) last month, the drug became the first oral treatment for prophylaxis to prevent hereditary angioedema (HAE) attacks. According to Zitter Insights, payers with nearly three-quarters of covered lives plan to manage it at parity to other prophylactic treatments.

HAE is a rare but potentially fatal condition that causes swelling in various parts of the body, including the hands, feet, intestinal tract, face, larynx and trachea.

© 2024 MMIT
Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

woman-holding-bowel
June 13

Studies Reveal Impact of SonarMD Program on Managing IBD

READ MORE
pills-and-bills
June 13

Report: Led by Anti-Inflammatories, Specialty Drugs Continue Upward Trend

READ MORE
fda-approved-rubber-stamp-with-fda-and-pills-on-craft-paper
June 13

New FDA Approvals: FDA Expanded Mircera’s Patient Population

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today